Drug intelligence / Profile preview

DXO-1803

Development stage: Unknown
Lead developer: Dexcel Pharma
Modality: Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Subcutaneous

Overview

DXO-1803 is an investigational small interfering RNA (siRNA) conjugated with N-acetylgalactosamine (GalNAc), developed by Dexoligo Therapeutics, a subsidiary of Dexcel Pharma. The GalNAc conjugation platform is designed to facilitate the targeted delivery of the siRNA to hepatocytes in the liver by binding to the asialoglycoprotein receptor (ASGPR). Once internalized, the siRNA utilizes the RNA interference (RNAi) pathway to silence the expression of a specific messenger RNA (mRNA). As of early 2024, DXO-1803 is in the discovery stage of development, and its specific biological target and primary therapeutic indication remain undisclosed by the developer.

Beyond the preview

Go deeper on DXO-1803.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DXO-1803.

Explore the full profile